CORMEDIX INC. Increase Decrease In Operating Lease Liability
CORMEDIX INC. (CRMD) reported Increase Decrease In Operating Lease Liability of -$308.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-03-05
- CORMEDIX INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$149.57K.
- CORMEDIX INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$76.67K.
- CORMEDIX INC. increase decrease in operating lease liability for the quarter ending 2025-06-30 was -$41.34K.
- CORMEDIX INC. increase decrease in operating lease liability for the quarter ending 2025-03-31 was -$40.42K.
- CORMEDIX INC. increase decrease in operating lease liability for fiscal 2025 was -$308.00K.
- CORMEDIX INC. increase decrease in operating lease liability for fiscal 2024 was -$151.00K.
- CORMEDIX INC. increase decrease in operating lease liability for fiscal 2023 was -$134.80K.
- CORMEDIX INC. increase decrease in operating lease liability for fiscal 2022 was -$121.37K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month | Increase Decrease In Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | -$149.57K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$226.23K derived: sum of 2 quarters · filed 2026-03-05 | -$267.57K derived: sum of 3 quarters · filed 2026-03-05 | -$308.00K 10-K · filed 2026-03-05 | |
| 2025-09-30 | -$76.67K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$118.01K derived: sum of 2 quarters · filed 2025-11-12 | -$158.43K 10-Q · filed 2025-11-12 | -$198.22K derived: sum of 4 quarters · filed 2026-03-05 | |
| 2025-06-30 | -$41.34K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$81.77K 10-Q · filed 2025-08-07 | -$121.55K derived: sum of 3 quarters · filed 2026-03-05 | -$159.46K derived: sum of 4 quarters · filed 2026-03-05 | |
| 2025-03-31 | -$40.42K 10-Q · filed 2025-05-06 | -$80.21K derived: sum of 2 quarters · filed 2026-03-05 | -$118.11K derived: sum of 3 quarters · filed 2026-03-05 | -$155.18K derived: sum of 4 quarters · filed 2026-03-05 | |
| 2024-12-31 | -$39.78K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$77.69K derived: sum of 2 quarters · filed 2026-03-05 | -$114.76K derived: sum of 3 quarters · filed 2026-03-05 | -$151.00K 10-K · filed 2026-03-05 | -$150.62K 10-K · filed 2025-03-25 |
| 2024-09-30 | -$37.91K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$74.97K derived: sum of 2 quarters · filed 2025-11-12 | -$111.22K 10-Q · filed 2025-11-12 | -$146.53K derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | -$37.07K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$73.31K 10-Q · filed 2025-08-07 | -$108.63K derived: sum of 3 quarters · filed 2025-08-07 | -$142.53K derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | -$36.24K 10-Q · filed 2025-05-06 | -$71.56K derived: sum of 2 quarters · filed 2025-05-06 | -$105.47K derived: sum of 3 quarters · filed 2025-05-06 | -$138.62K derived: sum of 4 quarters · filed 2025-05-06 | |
| 2023-12-31 | -$35.31K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | -$69.22K derived: sum of 2 quarters · filed 2025-03-25 | -$102.38K derived: sum of 3 quarters · filed 2025-03-25 | -$134.80K 10-K · filed 2025-03-25 | |
| 2023-09-30 | -$33.91K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | -$67.06K derived: sum of 2 quarters · filed 2024-10-30 | -$99.49K 10-Q · filed 2024-10-30 | -$131.06K derived: sum of 4 quarters · filed 2024-10-30 | |
| 2023-06-30 | -$33.16K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$65.58K 10-Q · filed 2024-08-14 | -$97.15K derived: sum of 3 quarters · filed 2024-08-14 | -$127.41K derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | -$32.42K 10-Q · filed 2024-05-09 | -$64.00K derived: sum of 2 quarters · filed 2024-05-09 | -$94.25K derived: sum of 3 quarters · filed 2024-05-09 | ||
| 2022-12-31 | -$31.58K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$61.83K derived: sum of 2 quarters · filed 2024-03-12 | -$121.37K 10-K · filed 2024-03-12 | ||
| 2022-09-30 | -$30.25K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$89.79K 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | -$59.54K 10-Q · filed 2023-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |